Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1994 Sep;72(3 Suppl):S92–S99. doi: 10.1136/hrt.72.3_suppl.s92

Inotropic agents for heart failure: what if digoxin increases mortality?

W J Remme 1
PMCID: PMC1025601  PMID: 7946812

Full text

PDF
S92

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen D. G., Kurihara S. Calcium transients in mammalian ventricular muscle. Eur Heart J. 1980;Suppl A:5–15. doi: 10.1093/eurheartj/1.suppl_1.5. [DOI] [PubMed] [Google Scholar]
  2. Anderson F. L., Port J. D., Reid B. B., Hanson G., Kralios A. C., Hershberger R. E., Bristow M. R. Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992;20(5):800–806. [PubMed] [Google Scholar]
  3. Aronow W. S., Starling L., Etienne F. Lack of efficacy of digoxin in treatment of compensated congestive heart failure with third heart sound and sinus rhythm in elderly patients receiving diuretic therapy. Am J Cardiol. 1986 Jul 1;58(1):168–169. doi: 10.1016/0002-9149(86)90264-x. [DOI] [PubMed] [Google Scholar]
  4. Assmann I., Kassel P., Duck H. G., Fiehring H., Morgan P., Schmidt P. K., Höfs T., Nehmiz G. Akut- und Langzeiteffekte von Pimobendan (UD-CG 115) bei Herzinsuffizienz NYHA II und III. Ergebnisse einer randomisierten multizentrischen Doppelblindstudie. Z Kardiol. 1991 Nov;80(11):687–694. [PubMed] [Google Scholar]
  5. Bloch K. D., Zamir N., Lichtstein D., Seidman C. E., Seidman J. G. Ouabain induces secretion of proatrial natriuretic factor by rat atrial cardiocytes. Am J Physiol. 1988 Sep;255(3 Pt 1):E383–E387. doi: 10.1152/ajpendo.1988.255.3.E383. [DOI] [PubMed] [Google Scholar]
  6. Borow K. M., Come P. C., Neumann A., Baim D. S., Braunwald E., Grossman W. Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease. Am J Cardiol. 1985 Apr 15;55(9):1204–1209. doi: 10.1016/0002-9149(85)90664-2. [DOI] [PubMed] [Google Scholar]
  7. Bristow M. R., Anderson F. L., Port J. D., Skerl L., Hershberger R. E., Larrabee P., O'Connell J. B., Renlund D. G., Volkman K., Murray J. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991 Sep;84(3):1024–1039. doi: 10.1161/01.cir.84.3.1024. [DOI] [PubMed] [Google Scholar]
  8. Bristow M. R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., Jamieson S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep;59(3):297–309. doi: 10.1161/01.res.59.3.297. [DOI] [PubMed] [Google Scholar]
  9. Bristow M. R., Hershberger R. E., Port J. D., Minobe W., Rasmussen R. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 1989 Mar;35(3):295–303. [PubMed] [Google Scholar]
  10. Bristow M. R., Minobe W., Rasmussen R., Hershberger R. E., Hoffman B. B. Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther. 1988 Dec;247(3):1039–1045. [PubMed] [Google Scholar]
  11. Busch F. W., Tillmann A., Becker E. W., Owsianowski M., Berg P. A. The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes. Eur J Clin Pharmacol. 1992;42(6):629–633. doi: 10.1007/BF00265927. [DOI] [PubMed] [Google Scholar]
  12. Böhm M., Diet F., Feiler G., Kemkes B., Erdmann E. Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol. 1988 Sep;12(3):357–364. doi: 10.1097/00005344-198809000-00015. [DOI] [PubMed] [Google Scholar]
  13. Böhm M., Diet F., Feiler G., Kemkes B., Kreuzer E., Weinhold C., Erdmann E. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation. J Cardiovasc Pharmacol. 1988 Dec;12(6):726–732. doi: 10.1097/00005344-198812000-00015. [DOI] [PubMed] [Google Scholar]
  14. Böhm M., Gierschik P., Jakobs K. H., Pieske B., Schnabel P., Ungerer M., Erdmann E. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990 Oct;82(4):1249–1265. doi: 10.1161/01.cir.82.4.1249. [DOI] [PubMed] [Google Scholar]
  15. Böhm M., Ungerer M., Erdmann E. Beta adrenoceptors and m-cholinoceptors in myocardium of hearts with coronary artery disease or idiopathic dilated cardiomyopathy removed at cardiac transplantation. Am J Cardiol. 1990 Oct 1;66(10):880–882. doi: 10.1016/0002-9149(90)90376-c. [DOI] [PubMed] [Google Scholar]
  16. Cody R. J., Müller F. B., Kubo S. H., Rutman H., Leonard D. Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure. Circulation. 1986 Jan;73(1):124–129. doi: 10.1161/01.cir.73.1.124. [DOI] [PubMed] [Google Scholar]
  17. Cooke J. P., Shepherd J. T., Vanhoutte P. M. Vasoconstriction induced by ouabain in the canine coronary artery: contribution of adrenergic and nonadrenergic responses. Cardiovasc Drugs Ther. 1988 Jul;2(2):255–263. doi: 10.1007/BF00051242. [DOI] [PubMed] [Google Scholar]
  18. Davies R. F., Beanlands D. S., Nadeau C., Phaneuf D., Morris A., Arnold J. M., Parker J. O., Baigrie R., Latour P., Klinke W. P. Enalapril versus digoxin in patients with congestive heart failure: a multicenter study. Canadian Enalapril Versus Digoxin Study Group. J Am Coll Cardiol. 1991 Dec;18(7):1602–1609. doi: 10.1016/0735-1097(91)90491-q. [DOI] [PubMed] [Google Scholar]
  19. DeMots H., Rahimtoola S. H., McAnulty J. H., Porter G. A. Effects of ouabain on coronary and systemic vascular resistance and myocardial oxygen consumption in patients without heart failure. Am J Cardiol. 1978 Jan;41(1):88–93. doi: 10.1016/0002-9149(78)90137-6. [DOI] [PubMed] [Google Scholar]
  20. DiBianco R., Shabetai R., Kostuk W., Moran J., Schlant R. C., Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989 Mar 16;320(11):677–683. doi: 10.1056/NEJM198903163201101. [DOI] [PubMed] [Google Scholar]
  21. DiBianco R., Shabetai R., Kostuk W., Moran J., Schlant R. C., Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989 Mar 16;320(11):677–683. doi: 10.1056/NEJM198903163201101. [DOI] [PubMed] [Google Scholar]
  22. Dilsizian V., Bonow R. O. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation. 1993 Jan;87(1):1–20. doi: 10.1161/01.cir.87.1.1. [DOI] [PubMed] [Google Scholar]
  23. Eschenhagen T., Mende U., Nose M., Schmitz W., Scholz H., Haverich A., Hirt S., Döring V., Kalmár P., Höppner W. Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure. Circ Res. 1992 Apr;70(4):688–696. doi: 10.1161/01.res.70.4.688. [DOI] [PubMed] [Google Scholar]
  24. Feldman A. M., Bristow M. R., Parmley W. W., Carson P. E., Pepine C. J., Gilbert E. M., Strobeck J. E., Hendrix G. H., Powers E. R., Bain R. P. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993 Jul 15;329(3):149–155. doi: 10.1056/NEJM199307153290301. [DOI] [PubMed] [Google Scholar]
  25. Feldman A. M., Cates A. E., Veazey W. B., Hershberger R. E., Bristow M. R., Baughman K. L., Baumgartner W. A., Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 1988 Jul;82(1):189–197. doi: 10.1172/JCI113569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ferguson D. W., Berg W. J., Sanders J. S., Roach P. J., Kempf J. S., Kienzle M. G. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation. 1989 Jul;80(1):65–77. doi: 10.1161/01.cir.80.1.65. [DOI] [PubMed] [Google Scholar]
  27. Fleg J. L., Rothfeld B., Gottlieb S. H. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 1991 Mar 1;17(3):743–751. doi: 10.1016/s0735-1097(10)80194-9. [DOI] [PubMed] [Google Scholar]
  28. Guyatt G. H., Sullivan M. J., Fallen E. L., Tihal H., Rideout E., Halcrow S., Nogradi S., Townsend M., Taylor D. W. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988 Feb 1;61(4):371–375. doi: 10.1016/0002-9149(88)90947-2. [DOI] [PubMed] [Google Scholar]
  29. Hajjar R. J., Gwathmey J. K. Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view. Cardiovasc Drugs Ther. 1991 Dec;5(6):961–965. doi: 10.1007/BF00143520. [DOI] [PubMed] [Google Scholar]
  30. Haleen S. J., Steffen R. P., Sircar I., Major T. C., Taylor M. D., Pugsley T. A., Weishaar R. E. PD 122860: a novel dihydropyridine with sodium channel stimulating and calcium channel blocking properties. J Pharmacol Exp Ther. 1989 Jul;250(1):22–30. [PubMed] [Google Scholar]
  31. Hasenfuss G., Holubarsch C., Heiss H. W., Meinertz T., Bonzel T., Wais U., Lehmann M., Just H. Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone. Circulation. 1989 Jul;80(1):51–64. doi: 10.1161/01.cir.80.1.51. [DOI] [PubMed] [Google Scholar]
  32. Hasenfuss G., Holubarsch C., Heiss H. W., Rattert B., Just H. Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside. Basic Res Cardiol. 1989;84 (Suppl 1):225–233. doi: 10.1007/BF02650362. [DOI] [PubMed] [Google Scholar]
  33. Holck M., Osterrieder W. Interaction of the cardiotonic agent DPI 201-106 with cardiac Ca2+ channels. J Cardiovasc Pharmacol. 1988 Apr;11(4):478–482. doi: 10.1097/00005344-198804000-00015. [DOI] [PubMed] [Google Scholar]
  34. Holubarsch C., Hasenfuss G., Just H., Blanchard E., Mulieri L. A., Alpert N. R. Influence of the positive inotropic substance pimobendan (UD-CG 115 BS) on contractile economy of guinea pig papillary muscles. J Cardiovasc Pharmacol. 1989;14 (Suppl 2):S13–S17. [PubMed] [Google Scholar]
  35. Indolfi C., Piscione F., Russolillo E., Villari B., Golino P., Ambrosini V., Condorelli M., Chiariello M. Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries. Am J Cardiol. 1991 Nov 15;68(13):1274–1278. doi: 10.1016/0002-9149(91)90230-i. [DOI] [PubMed] [Google Scholar]
  36. Katz S. D., Kubo S. H., Jessup M., Brozena S., Troha J. M., Wahl J., Cohn J. N., Sonnenblick E. H., LeJemtel T. H. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J. 1992 Jan;123(1):95–103. doi: 10.1016/0002-8703(92)90752-h. [DOI] [PubMed] [Google Scholar]
  37. Kubo S. H., Gollub S., Bourge R., Rahko P., Cobb F., Jessup M., Brozena S., Brodsky M., Kirlin P., Shanes J. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation. 1992 Mar;85(3):942–949. doi: 10.1161/01.cir.85.3.942. [DOI] [PubMed] [Google Scholar]
  38. Landzberg J. S., Parker J. D., Gauthier D. F., Colucci W. S. Effects of myocardial alpha 1-adrenergic receptor stimulation and blockade on contractility in humans. Circulation. 1991 Oct;84(4):1608–1614. doi: 10.1161/01.cir.84.4.1608. [DOI] [PubMed] [Google Scholar]
  39. Lee D. C., Johnson R. A., Bingham J. B., Leahy M., Dinsmore R. E., Goroll A. H., Newell J. B., Strauss H. W., Haber E. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 1982 Mar 25;306(12):699–705. doi: 10.1056/NEJM198203253061202. [DOI] [PubMed] [Google Scholar]
  40. Leier C. V., Huss P., Lewis R. P., Unverferth D. V. Drug-induced conditioning in congestive heart failure. Circulation. 1982 Jun;65(7):1382–1387. doi: 10.1161/01.cir.65.7.1382. [DOI] [PubMed] [Google Scholar]
  41. Lown B., Graboys T. B., Podrid P. J., Cohen B. H., Stockman M. B., Gaughan C. E. Effect of a digitalis drug on ventricular premature beats. N Engl J Med. 1977 Feb 10;296(6):301–306. doi: 10.1056/NEJM197702102960603. [DOI] [PubMed] [Google Scholar]
  42. Ludmer P. L., Wright R. F., Arnold J. M., Ganz P., Braunwald E., Colucci W. S. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation. 1986 Jan;73(1):130–137. doi: 10.1161/01.cir.73.1.130. [DOI] [PubMed] [Google Scholar]
  43. MASON D. T., BRAUNWALD E. STUDIES ON DIGITALIS. X. EFFECTS OF OUABAIN ON FOREARM VASCULAR RESISTANCE AND VENOUS TONE IN NORMAL SUBJECTS AND IN PATIENTS IN HEART FAILURE. J Clin Invest. 1964 Mar;43:532–543. doi: 10.1172/JCI104939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Massie B., Bourassa M., DiBianco R., Hess M., Konstam M., Likoff M., Packer M. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation. 1985 May;71(5):963–971. doi: 10.1161/01.cir.71.5.963. [DOI] [PubMed] [Google Scholar]
  45. Mettauer B., Rouleau J. L., Burgess J. H. Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am Heart J. 1985 Apr;109(4):840–847. doi: 10.1016/0002-8703(85)90648-9. [DOI] [PubMed] [Google Scholar]
  46. Muir A. L., Nolan J. Modulation of venous tone in heart failure. Am Heart J. 1991 Jun;121(6 Pt 2):1948–1950. doi: 10.1016/0002-8703(91)90830-b. [DOI] [PubMed] [Google Scholar]
  47. Packer M., Gheorghiade M., Young J. B., Costantini P. J., Adams K. F., Cody R. J., Smith L. K., Van Voorhees L., Gourley L. A., Jolly M. K. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993 Jul 1;329(1):1–7. doi: 10.1056/NEJM199307013290101. [DOI] [PubMed] [Google Scholar]
  48. Remme W. J. Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations. Cardiovasc Drugs Ther. 1989 Jun;3(3):375–396. doi: 10.1007/BF01858109. [DOI] [PubMed] [Google Scholar]
  49. Remme W. J., Wiesfeld A. C., Look M. P., Kruyssen H. A. Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction. J Cardiovasc Pharmacol. 1989;14 (Suppl 2):S41–S44. [PubMed] [Google Scholar]
  50. Remme W. J., van Hoogenhuyze D. C., Kruijssen H. A., Pieper P. G., Bruggeling W. A. Preload-dependent hemodynamic effects of milrinone in moderate heart failure. Cardiology. 1992;80(2):132–142. doi: 10.1159/000174991. [DOI] [PubMed] [Google Scholar]
  51. Rousseau M. F., Raigoso J., van Eyll C., Van Mechelen H., Musso N. R., Lotti G., Pouleur H. Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. J Cardiovasc Pharmacol. 1992 Feb;19(2):155–162. doi: 10.1097/00005344-199202000-00001. [DOI] [PubMed] [Google Scholar]
  52. Scheld H. H., Fritsche R., Schlepper M., van Meel J. C. Pimobendan increases calcium sensitivity of skinned human papillary muscle fibers. J Clin Pharmacol. 1989 Apr;29(4):360–366. doi: 10.1002/j.1552-4604.1989.tb03342.x. [DOI] [PubMed] [Google Scholar]
  53. Schnabel P., Böhm M., Gierschik P., Jakobs K. H., Erdmann E. Improvement of cholera toxin-catalyzed ADP-ribosylation by endogenous ADP-ribosylation factor from bovine brain provides evidence for an unchanged amount of Gs alpha in failing human myocardium. J Mol Cell Cardiol. 1990 Jan;22(1):73–82. doi: 10.1016/0022-2828(90)90973-6. [DOI] [PubMed] [Google Scholar]
  54. Schramm M., Thomas G., Towart R., Franckowiak G. Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature. 1983 Jun 9;303(5917):535–537. doi: 10.1038/303535a0. [DOI] [PubMed] [Google Scholar]
  55. Silver P. J., Allen P., Etzler J. H., Hamel L. T., Bentley R. G., Pagani E. D. Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects. Second Messengers Phosphoproteins. 1990;13(1):13–25. [PubMed] [Google Scholar]
  56. Taggart A. J., Johnston G. D., McDevitt D. G. Digoxin withdrawal after cardiac failure in patients with sinus rhythm. J Cardiovasc Pharmacol. 1983 Mar-Apr;5(2):229–234. doi: 10.1097/00005344-198303000-00011. [DOI] [PubMed] [Google Scholar]
  57. Uretsky B. F., Jessup M., Konstam M. A., Dec G. W., Leier C. V., Benotti J., Murali S., Herrmann H. C., Sandberg J. A. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation. 1990 Sep;82(3):774–780. doi: 10.1161/01.cir.82.3.774. [DOI] [PubMed] [Google Scholar]
  58. Uretsky B. F., Young J. B., Shahidi F. E., Yellen L. G., Harrison M. C., Jolly M. K. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993 Oct;22(4):955–962. doi: 10.1016/0735-1097(93)90403-n. [DOI] [PubMed] [Google Scholar]
  59. Weber K. T., Andrews V., Janicki J. S., Likoff M., Reichek N. Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. Circulation. 1982 Dec;66(6):1262–1267. doi: 10.1161/01.cir.66.6.1262. [DOI] [PubMed] [Google Scholar]
  60. Wilkie D. R. Muscular fatigue: effects of hydrogen ions and inorganic phosphate. Fed Proc. 1986 Dec;45(13):2921–2923. [PubMed] [Google Scholar]
  61. Yanagisawa T., Ishii K., Taira N. Antitachycardiac effect of OPC-8212, a novel cardiotonic agent, on tachycardiac responses of guinea pig isolated right atria to isoproterenol and histamine. J Cardiovasc Pharmacol. 1987 Jul;10(1):47–54. doi: 10.1097/00005344-198707000-00007. [DOI] [PubMed] [Google Scholar]
  62. van Veldhuisen D. J., Man in 't Veld A. J., Dunselman P. H., Lok D. J., Dohmen H. J., Poortermans J. C., Withagen A. J., Pasteuning W. H., Brouwer J., Lie K. I. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol. 1993 Nov 15;22(6):1564–1573. doi: 10.1016/0735-1097(93)90579-p. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES